The Office of the Vice President for Research (OVPR) recently announced recipients in the inaugural funding round for the Program in Accelerated Therapeutics for Healthcare (PATH). PATH is a partnership that includes the OVPR, the School of Pharmacy, and the School of Medicine to accelerate the translational pathway for researchers to convert their discoveries to new medical therapeutics.<\/p>\n
Under PATH, funding is provided to academic research programs designed to quickly develop novel therapeutic approaches focusing on well validated molecular targets for specific disease areas with an unmet treatment need in the current commercial marketplace. Projects focusing on a wide range of therapeutic interventions (small molecule, biologic, antibody, peptide, gene therapy) are eligible for consideration.<\/p>\n
Seven PATH grants were awarded in two categories after a selective competition.<\/p>\n
Xiuling Lu, <\/strong>Pharmaceutical Science Jessica Rouge, <\/strong>Chemistry Brian Aneskievich, <\/strong>Pharmaceutical Science Nicholas Leadbeater, <\/strong>Chemistry Rajkumar Verma, <\/strong>Neuroscience, UConn Health Simon White, <\/strong>Molecular and Cell Biology Ming Xu, <\/strong>Genetics and Genome Sciences, UConn Health For more information about PATH, visit the program website.<\/a><\/p>\n <\/p>\n Follow UConn Research on <\/em>Twitter<\/em><\/a> & <\/em>LinkedIn<\/em><\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" PATH is a partnership that includes the OVPR, the School of Pharmacy, and the School of Medicine to accelerate the translational pathway for researchers to convert their discoveries to new medical therapeutics. <\/p>\n","protected":false},"author":127,"featured_media":150296,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","wds_primary_category":0,"wds_primary_series":0,"wds_primary_attribution":0,"footnotes":""},"categories":[2226,2076,1868,1864],"tags":[],"magazine-issues":[],"coauthors":[2140],"class_list":["post-150295","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clas","category-research","category-meds","category-pharm"],"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-27 18:32:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts\/150295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/users\/127"}],"replies":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/comments?post=150295"}],"version-history":[{"count":0,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/posts\/150295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/media\/150296"}],"wp:attachment":[{"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/media?parent=150295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/categories?post=150295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/tags?post=150295"},{"taxonomy":"magazine-issue","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/magazine-issues?post=150295"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/today.uconn.edu\/wp-rest\/wp\/v2\/coauthors?post=150295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n<\/strong>Cutting Cancer at Its Root: Inhibition of Acute Leukemic Stem Cells Using Doxorubicin-Loaded Nanoparticles\u00a0<\/em><\/p>\n
\nDetermining the pharmacology of a novel DNAzyme-therapeutic formulation for the treatment of allergic airway disease<\/em><\/p>\nPATH Ascent Grants – $10,000<\/h3>\n
\nEstablishing Protein Conformational Flexibility to Enhance Next-Step Drug-Screen Targeting<\/em><\/p>\n
\n<\/strong>Towards Development of Novel Therapeutics for Treatment of Toxoplasmosis<\/em><\/p>\n
\nDiscovery of novel purinergic P2X4 receptor antagonist for the treatment of ischemic stroke<\/em><\/p>\n
\nScreening for small molecule inhibitors against Enterovirus D68 2C helicase<\/em><\/p>\n
\nDiscover drugs targeting cellular senescence to improve healthspan and lifespan<\/em><\/p>\n